Our Services
Medical Information
Helpful Resources
Published on: 9/12/2026
Zepbound (tirzepatide) carries a boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma, seen in rodent studies, and pancreatitis has been reported in people using it, though both risks are considered rare and unconfirmed in humans. Warning signs of pancreatitis include severe, persistent upper abdominal pain that may radiate to the back, often with nausea or vomiting, while possible thyroid tumor signs include a neck lump or swelling, hoarseness, trouble swallowing, or shortness of breath. Your personal risk depends on factors like a family history of medullary thyroid carcinoma, MEN2 syndrome, prior pancreatitis, gallstones, and heavy alcohol use, so there are several important details to consider below before deciding what to do next.
Because these symptoms overlap with far more common and less serious causes, guessing can lead to unnecessary panic or a dangerous delay, and knowing which signs warrant urgent care matters. Take a free, instant, online symptom check to clarify what your symptoms may mean and get guidance on the right next steps.
Last reviewed for medical accuracy: 09/11/2026
Zepbound (tirzepatide) is a prescription injectable medication approved to help manage type 2 diabetes and support weight loss in certain adults. Like all drugs, Zepbound side effects can range from mild to serious. Two of the concerns people often ask about are pancreatitis (inflammation of the pancreas) and thyroid cancer. This guide explains what we know, outlines warning signs, and helps you decide when to seek medical advice.
Pancreatitis means inflammation of the pancreas, an organ behind the stomach that helps digest food and regulate blood sugar. It can be acute (sudden) or chronic (long-term).
Watch for symptoms that require immediate medical attention:
If you experience these signs, stop Zepbound (unless your doctor advises otherwise) and seek emergency care.
Studies in rats found that drugs in the GLP-1 class can cause thyroid C-cell tumors. While rodents are more sensitive, human risk can’t be dismissed entirely.
Early thyroid cancers often cause no symptoms. Still, be alert to:
If you notice any of these, talk to your doctor for evaluation.
While pancreatitis and thyroid concerns are among the more serious, Zepbound can also cause:
Most people find these side effects mild to moderate, often improving over weeks as the body adjusts.
When considering any medication, weigh potential benefits against possible risks:
Benefits of Zepbound
Risks to Keep in Mind
Your healthcare provider can help decide if Zepbound is right for you based on your medical history and personal risk factors.
To reduce risk and catch complications early:
Before Starting Zepbound
During Treatment
Not every stomach ache or throat irritation is serious, but it’s best to err on the side of caution:
Zepbound offers meaningful benefits for blood sugar control and weight management, but like any powerful medication, it carries potential risks. Pancreatitis and thyroid cancer are rare but serious concerns to keep in mind.
Your health journey is a partnership. With careful monitoring and open communication, you and your healthcare team can make the safest, most effective choices for your care.
(References)
* Mishra R, Raj R, Elshimy G, Zapata I, Kannan L, Majety P, Edem D, Correa R. Adverse Events Related to Tirzepatide. J Endocr Soc. 2023 Feb 9;7(4):bvad016. doi: 10.1210/jendso/bvad016. Epub 2023 Jan 26. PMID: 36789109; PMCID: PMC9915969.
* Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. doi: 10.3389/fendo.2023.1214334. Epub 2023 Oct 16. PMID: 37908750; PMCID: PMC10613702.
* Cai W, Zhang R, Yao Y, Wu Q, Zhang J. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Front Public Health. 2024;12:1277113. doi: 10.3389/fpubh.2024.1277113. Epub 2024 Jan 31. PMID: 38356942; PMCID: PMC10864442.
* Caruso I, Di Gioia L, Di Molfetta S, Caporusso M, Cignarelli A, Sorice GP, Laviola L, Giorgino F. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. J Endocrinol Invest. 2024 Nov;47(11):2671-2678. doi: 10.1007/s40618-024-02441-z. Epub 2024 Aug 14. PMID: 39141075; PMCID: PMC11473560.
* Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024 Dec;12:100127. doi: 10.1016/j.obpill.2024.100127. Epub 2024 Aug 31. PMID: 39286601; PMCID: PMC11404059.
* Guo H, Guo Q, Li Z, Wang Z. Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis. Front Pharmacol. 2024;15:1461398. doi: 10.3389/fphar.2024.1461398. Epub 2024 Nov 13. PMID: 39605914; PMCID: PMC11600108.
* Himmerich H. [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]. Nervenarzt. 2025 May;96(3):247-254. doi: 10.1007/s00115-025-01813-x. Epub 2025 Mar 5. PMID: 40042613; PMCID: PMC12058874.
* Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8. PMID: 40196933; PMCID: PMC12000858.
* Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, Rocco E, Bernardi M, Spadafora L, D'Amario D, Greco E, Frati G, Federici M, Mehran R, Crea F, Angiolillo DJ, Sciarretta S. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025 Nov 18;86(20):1805-1819. doi: 10.1016/j.jacc.2025.08.027. Epub 2025 Aug 27. PMID: 40892610.
* Ko A, Chang YC, Bahar F, Wang TH, Xanthavanij N, Yu CC, Hsieh RJ, See XY, Lo SW, Song J, Hsia YP, Chiang CH, Xu X, Lin S, Chiang CH. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis. Ann Intern Med. 2026 Feb;179(2):216-229. doi: 10.7326/ANNALS-25-02237. Epub 2025 Dec 9. PMID: 41359966.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.